These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21499794)

  • 41. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.
    Kalayjian RC; Lau B; Mechekano RN; Crane HM; Rodriguez B; Salata RA; Krishnasami Z; Willig JH; Martin JN; Moore RD; Eron JJ; Kitahata MM
    AIDS; 2012 Sep; 26(15):1907-15. PubMed ID: 22824630
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.
    Nichols SL; Bethel J; Kapogiannis BG; Li T; Woods SP; Patton ED; Ren W; Thornton SE; Major-Wilson HO; Puga AM; Sleasman JW; Rudy BJ; Wilson CM; Garvie PA;
    J Neurovirol; 2016 Apr; 22(2):218-30. PubMed ID: 26463526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis.
    Nachega JB; Uthman OA; Anderson J; Peltzer K; Wampold S; Cotton MF; Mills EJ; Ho YS; Stringer JS; McIntyre JA; Mofenson LM
    AIDS; 2012 Oct; 26(16):2039-52. PubMed ID: 22951634
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection.
    Nieuwkerk PT; Gisolf EH; Reijers MH; Lange JM; Danner SA; Sprangers MA; ; ;
    AIDS; 2001 Oct; 15(15):1985-91. PubMed ID: 11600827
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
    Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa.
    Coetzee D; Hildebrand K; Boulle A; Maartens G; Louis F; Labatala V; Reuter H; Ntwana N; Goemaere E
    AIDS; 2004 Apr; 18(6):887-95. PubMed ID: 15060436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries.
    Pujades-Rodríguez M; Balkan S; Arnould L; Brinkhof MA; Calmy A;
    JAMA; 2010 Jul; 304(3):303-12. PubMed ID: 20639564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Brief Report: Impact of Early Antiretroviral Therapy on the Performance of HIV Rapid Tests and HIV Incidence Assays.
    Fogel JM; Piwowar-Manning E; Debevec B; Walsky T; Schlusser K; Laeyendecker O; Wilson EA; McCauley M; Gamble T; Tegha G; Soko D; Kumwenda J; Hosseinipour MC; Chen YQ; Cohen MS; Eshleman SH
    J Acquir Immune Defic Syndr; 2017 Aug; 75(4):426-430. PubMed ID: 28471839
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lives saved by expanding HIV treatment availability in resource-limited settings: the example of Haiti.
    Kimmel AD; Charles M; Deschamps MM; Severe P; Edwards AM; Johnson WD; Fitzgerald DW; Pape JW; Schackman BR
    J Acquir Immune Defic Syndr; 2013 Jun; 63(2):e40-8. PubMed ID: 23535289
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa.
    Keiser O; Chi BH; Gsponer T; Boulle A; Orrell C; Phiri S; Maxwell N; Maskew M; Prozesky H; Fox MP; Westfall A; Egger M;
    AIDS; 2011 Sep; 25(14):1761-9. PubMed ID: 21681057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term virologic responses to antiretroviral therapy among HIV-positive patients entering adherence clubs in Khayelitsha, Cape Town, South Africa: a longitudinal analysis.
    Kehoe K; Boulle A; Tsondai PR; Euvrard J; Davies MA; Cornell M
    J Int AIDS Soc; 2020 May; 23(5):e25476. PubMed ID: 32406983
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature.
    Ivers LC; Kendrick D; Doucette K
    Clin Infect Dis; 2005 Jul; 41(2):217-24. PubMed ID: 15983918
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
    Paredes R; Mocroft A; Kirk O; Lazzarin A; Barton SE; van Lunzen J; Katzenstein TL; Antunes F; Lundgren JD; Clotet B
    Arch Intern Med; 2000 Apr; 160(8):1123-32. PubMed ID: 10789605
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
    Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
    J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of CD4+ T cell count and antiretroviral treatment on two serological HIV incidence assays.
    Hladik W; Olara D; Mermin J; Moore D; Were W; Alexander L; Downing R
    AIDS Res Hum Retroviruses; 2012 Jan; 28(1):95-9. PubMed ID: 21314476
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
    Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
    HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High CD4 counts associated with better economic outcomes for HIV-positive adults and their HIV-negative household members in the SEARCH Trial.
    Jakubowski A; Snyman K; Kwarisiima D; Sang N; Burger R; Balzer L; Clark T; Chamie G; Shade S; Cohen C; Bukusi E; Charlebois E; Kamya M; Petersen M; Havlir D; Thirumurthy H
    PLoS One; 2018; 13(6):e0198912. PubMed ID: 29944678
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Health-Related Quality of Life in Patients Treated With Antiretroviral Therapy Only Versus Chemotherapy and Antiretroviral Therapy for HIV-Associated Kaposi Sarcoma: A Randomized Control Trial.
    Shaik F; Uldrick TS; Esterhuizen T; Mosam A
    J Glob Oncol; 2018 Oct; 4():1-9. PubMed ID: 30354935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
    Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
    Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania.
    Mosha F; Muchunguzi V; Matee M; Sangeda RZ; Vercauteren J; Nsubuga P; Lyamuya E; Vandamme AM
    BMC Public Health; 2013 Jan; 13():38. PubMed ID: 23320567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.